News Presentations Publications

FILTERS

TOPICS

CritiTech Particle Engineering Solutions and Aeon Respire Announce Collaboration to Develop Novel Inhaled Formulation of Niclosamide

LAWRENCE, KS – January 25, 2022 – CritiTech Particle Engineering Solutions (“CritiTech”) has entered into a strategic collaboration and licensing … Continued

More >

AUA2021 Presentation Highlights Results from a Phase 1/2 Clinical Trial of Intramural/Intravesical NanoDoce® Suspension in High-Risk Nonmuscle Invasive Bladder Cancer by CritiTech PES Partner NanOlogy

FORT WORTH (September 21, 2021) — NanOlogy LLC, a clinical-stage interventional oncology drug company, announced today that initial results from a … Continued

More >

CritiTech PES Partner Nanology Presents Additional Data at DDW® 2021 from a Phase 2 Clinical Trial of Intracystic NanoPac® for Mucinous Cystic Neoplasms of the Pancreas

FORT WORTH, Texas–(BUSINESS WIRE)–NanOlogy, LLC, a clinical-stage oncology company, announced today that additional data from its Phase 2 dose-rising and … Continued

More >

CritiTech PES Partner NanOlogy Announces First Patient Enrollment in Lung Cancer Clinical Trial

FT. WORTH, (April 27, 2021) — NanOlogy, LLC, a clinical-stage interventional oncology drug therapy company, announced today the first patient has … Continued

More >

CritiTech PES partner NanOlogy Completes Enrollment of Bladder Cancer Clinical Trial

FT. WORTH, (March 9, 2021) — NanOlogy, LLC, a clinical-stage oncology company, today announced that enrollment has been completed in its … Continued

More >

CritiTech PES partner NanOlogy Presents Results of SOR007 (Topical Submicron Particle Paclitaxel) Phase 1/2 Clinical Trial in the Treatment of Cutaneous Metastases at 2020 SABCS®

FT. WORTH, (December 29, 2020) — NanOlogy, LLC, a clinical-stage oncology company, today announced that results from its Phase 1/2 clinical … Continued

More >

CritiTech PES partner NanOlogy Enrolls First Patient in Phase 2 Clinical Trial of NanoPac® for Intratumoral Treatment of Prostate Cancer

Follows completion of a first-in-human dose-rising study of a single focal injection of NanoPac in patients with local prostate cancer … Continued

More >

CritiTech PES partner NanOlogy Announces Initiation of a Lung Cancer Clinical Trial Following FDA Allowances of Two IND Applications for NanoPac® in Lung Cancer

First-in-human clinical trial of intratumoral (IT) injections of NanoPac in non-small cell lung cancer (NSCLC) and small cell lung cancer … Continued

More >

CritiTech PES partner NanOlogy Presents Updated Clinical Data on Targeted Injections of NanoPac® for Pancreatic Cancer and Mucinous Cystic Neoplasms on DDW2020 Site

Updated clinical data from both trials available through Digestive Disease Week® (DDW) Online Education Site FT. WORTH, (May 14, 2020) — NanOlogy, … Continued

More >

NanOlogy Fact Sheet (Jan 2020)

In patients with solid carcinomas, NanOlogy™ has demonstrated that local administration of patented submicron particles continuously exposes primary tumors to … Continued

More >